Business, energy, technology, markets and global industry news from Business News Today

digital pathology

PharmaDeviceNews digital pathology
Representative image of AI-powered digital pathology being used to analyse prostate cancer biopsy slides, reflecting Acupath Laboratories’ integration of the ArteraAI Prostate Test into its diagnostic workflow for localized prostate cancer risk stratification.
Medical Devices & Diagnostics

What Acupath’s ArteraAI Prostate Test rollout reveals about the next phase of precision oncology

Acupath adds ArteraAI Prostate Test to its pathology workflow. Find out what it means for AI prostate cancer risk stratification today.

Read More
Representative image: AI-powered digital pathology analysis for bladder cancer risk testing, highlighting how Valar Labs’ Vesta Bladder Risk Stratify Dx could support more precise non-muscle invasive bladder cancer prognosis after receiving FDA Breakthrough Device Designation.
Medical Devices & Diagnostics

Valar Labs FDA breakthrough nod signals new test for AI-led bladder cancer risk prediction

Bladder cancer risk tools leave gray zones. Valar Labs’ FDA breakthrough nod tests whether AI pathology can narrow them.

Read More
Representative image: AI-powered digital pathology analysis could help reshape breast cancer risk stratification after ArteraAI Breast became the first FDA-cleared pathology-based breast cancer risk tool in the United States.
Medical Devices & Diagnostics

Can ArteraAI Breast turn routine pathology slides into breast cancer risk intelligence?

AI can read pathology slides, but can it change breast cancer treatment decisions? ArteraAI Breast puts that question before clinicians and payers.

Read More
Representative image: Roche’s $1.05bn PathAI acquisition highlights how AI-powered digital pathology could accelerate tissue analysis, companion diagnostics, and precision oncology workflows across modern diagnostics laboratories.
Medical Devices & Diagnostics

What Roche’s $1.05bn PathAI move reveals about the future of pathology labs

Roche wants AI pathology at scale. PathAI gives it the tissue-analysis layer needed to tighten diagnostics, trials, and precision oncology.

Read More
Representative image of AI-powered digital pathology and oncology biomarker analysis, illustrating how Daiichi Sankyo and Waiv’s ADC collaboration could support smarter patient selection in precision cancer drug development.
Pharma & Biotech

Why Daiichi Sankyo’s Waiv collaboration matters for the next phase of ADC oncology trials

ADC trials need sharper patient selection. Daiichi Sankyo’s Waiv deal tests whether AI pathology can find response signals earlier.

Read More
Medical Devices & Diagnostics

Artera’s EU breakthrough in AI cancer testing opens a bigger battle over workflow, trust, and scale

Artera has won CE marking for its AI prostate and breast cancer assays. Read what this means for oncology diagnostics, adoption, and global expansion.

Read More
Medical Devices & Diagnostics

Ibex–HNL Lab Medicine deal signals shift from digital pathology to embedded AI decision support in U.S. diagnostics

Ibex partners with HNL Lab Medicine to deploy AI in prostate cancer diagnostics. Discover what this means for pathology workflows and adoption.

Read More
Medical Devices & Diagnostics

Fulgent Genetics acquires Bako Diagnostics and StrataDx to offset precision diagnostics headwind

Fulgent Genetics closes $56.9M Bako and StrataDx acquisition. What it means for anatomic pathology growth, margin risk, and diagnostic consolidation in 2026.

Read More
Medical Devices & Diagnostics

Can Agilent’s new slide scanner system shift digital pathology from pilot to mainstream in Europe?

Agilent’s new S540MD slide scanner targets scale and AI integration in European pathology labs. Find out what this means for digitisation strategy.

Read More
Medical Devices & Diagnostics

Fulgent Genetics acquires Bako Diagnostics and StrataDx to expand AI pathology strategy

Fulgent Genetics acquires Bako Diagnostics and StrataDx to scale AI pathology, expand national reach, and advance precision medicine strategy. Read full analysis.

Read More